JP2006503017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503017A5 JP2006503017A5 JP2004532284A JP2004532284A JP2006503017A5 JP 2006503017 A5 JP2006503017 A5 JP 2006503017A5 JP 2004532284 A JP2004532284 A JP 2004532284A JP 2004532284 A JP2004532284 A JP 2004532284A JP 2006503017 A5 JP2006503017 A5 JP 2006503017A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- sequence
- immunogen
- immunogenic composition
- substitutions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0220212A GB0220212D0 (en) | 2002-08-30 | 2002-08-30 | Vaccine |
| GB0304672A GB0304672D0 (en) | 2003-02-28 | 2003-02-28 | Vaccines |
| PCT/GB2003/003703 WO2004019974A2 (en) | 2002-08-30 | 2003-08-28 | Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006503017A JP2006503017A (ja) | 2006-01-26 |
| JP2006503017A5 true JP2006503017A5 (enExample) | 2006-06-15 |
Family
ID=31980003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004532284A Pending JP2006503017A (ja) | 2002-08-30 | 2003-08-28 | Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060147417A1 (enExample) |
| EP (1) | EP1532172A2 (enExample) |
| JP (1) | JP2006503017A (enExample) |
| AR (1) | AR041086A1 (enExample) |
| AU (1) | AU2003259358A1 (enExample) |
| CA (1) | CA2496409A1 (enExample) |
| TW (1) | TW200407162A (enExample) |
| WO (1) | WO2004019974A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006501249A (ja) * | 2002-08-30 | 2006-01-12 | グラクソ グループ リミテッド | ワクチン |
| MX361174B (es) | 2003-12-23 | 2018-11-29 | Genentech Inc | Anticuerpos anti-il13 novedosos y sus usos. |
| DE102004003572A1 (de) * | 2004-01-23 | 2005-08-18 | Bavarian Nordic A/S | Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens |
| KR100639397B1 (ko) * | 2004-03-18 | 2006-10-26 | (주)에스제이바이오메드 | 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물 |
| WO2006055638A2 (en) | 2004-11-17 | 2006-05-26 | Abgenix, Inc. | Fully human monoclonal antibodies to il-13 |
| GB0615881D0 (en) * | 2006-08-10 | 2006-09-20 | Univ Southampton | Novel peptide for treatment of asthma |
| MX2009003188A (es) * | 2006-09-25 | 2009-05-22 | Sj Biomedic Inc | Polipeptidos hibridos inmunogenicos antiobesidad y composicion de vacuna antiobesidad que comprende los mismos. |
| AU2010269120B2 (en) * | 2009-07-06 | 2015-09-24 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
| WO2015017034A1 (en) * | 2013-08-02 | 2015-02-05 | Gourdie Robert G | Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction |
| PL3044323T3 (pl) | 2013-09-13 | 2022-06-27 | F.Hoffmann-La Roche Ag | Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych |
| SG11201601823TA (en) | 2013-09-13 | 2016-04-28 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| WO2019061297A1 (zh) * | 2017-09-29 | 2019-04-04 | 苏州工业园区唯可达生物科技有限公司 | 一种cd4辅助性t细胞表位融合肽及其疫苗 |
| EP3574915A1 (en) | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
| MX2021007906A (es) | 2018-12-28 | 2021-10-13 | United Biomedical Inc | Nmunógenos peptídicos dirigidos a la interleucina 6 (il-6) y sus formulaciones para la inmunoterapia de enfermedades afectadas por la desregulación de la il-6. |
| WO2022114810A1 (ko) * | 2020-11-26 | 2022-06-02 | 재단법인 아산사회복지재단 | 프로그래뉼린 단백질 또는 이의 활성 단편을 유효성분으로 포함하는 섬유화 질환 예방 또는 치료용 약학 조성물 |
| AU2022215119A1 (en) * | 2021-01-29 | 2023-08-17 | Bayer Animal Health Gmbh | Vaccine composition for breaking self-tolerance |
| CA3229324A1 (en) * | 2021-08-20 | 2023-02-23 | Beatrice DROUET | Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| US6296843B1 (en) * | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
| EE200100552A (et) * | 1999-04-23 | 2002-12-16 | Pharmexa A/S | Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks |
| WO2001034645A2 (en) * | 1999-11-11 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Mutated il-13 molecules and their uses |
| US6846486B1 (en) * | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| GB0105360D0 (en) * | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
-
2003
- 2003-08-28 CA CA002496409A patent/CA2496409A1/en not_active Abandoned
- 2003-08-28 EP EP03791019A patent/EP1532172A2/en not_active Withdrawn
- 2003-08-28 AU AU2003259358A patent/AU2003259358A1/en not_active Abandoned
- 2003-08-28 WO PCT/GB2003/003703 patent/WO2004019974A2/en not_active Ceased
- 2003-08-28 US US10/526,060 patent/US20060147417A1/en not_active Abandoned
- 2003-08-28 JP JP2004532284A patent/JP2006503017A/ja active Pending
- 2003-08-28 TW TW092123745A patent/TW200407162A/zh unknown
- 2003-08-28 AR ARP030103127A patent/AR041086A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Theisen et al. | Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli | |
| CA1340472C (en) | Universal t-cell epitope derived from p. faciparum circumsporosoite protein | |
| EP1092774B1 (en) | Borrelia burgdorferi OspA polypeptide for immunization against Lyme disease | |
| AU637049B2 (en) | Recombinant flagellin vaccines | |
| JP2002525060A5 (enExample) | ||
| PT1076662E (pt) | Proteínas transportadoras de poli-epítopos | |
| WO1992000055A1 (en) | Compositions and methods for the prevention and diagnosis of lyme disease | |
| CA2565925C (en) | Vaccine for periodontal disease | |
| JP2005502314A5 (enExample) | ||
| WO1988005051A1 (en) | Synthetic peptides which induce cellular immunity of the aids virus and aids viral proteins | |
| JP2012516140A5 (enExample) | ||
| JPS6251994A (ja) | クロ−ン化抗原 | |
| EP3029073B1 (en) | Polyvalent chimeric ospc vaccinogen and diagnostic antigen | |
| JPH08509371A (ja) | ライム病の予防及び治療のためのＯｓｐＣ抗原ワクチンの免疫原性製剤及びかかる抗原の調製のための組換え方法 | |
| JP2006501249A5 (enExample) | ||
| JPH02291271A (ja) | 発現伝播体を有する組成物 | |
| US20190117756A1 (en) | Immunogenic Compositions and Vaccines Derived From Bacterial Surface Receptor Proteins | |
| JP3135060B2 (ja) | ヘモフィルスインフルエンザｂ型菌の外皮膜タンパク質Ｐ２の部分断片を用いた接合体 | |
| US20220202924A1 (en) | Compositions and treatments for haemophilus influenzae | |
| CN101880328A (zh) | 微小隐孢子虫Th多表位基因和融合蛋白及其应用 | |
| JPH02223594A (ja) | ヒトライノウイルスペプチド | |
| AU2001271124B2 (en) | Peptides for the preparation of vaccines against bordetella pertussis and bordetella parapertussis | |
| CN1187372C (zh) | 人绒毛膜促性腺激素基因工程合成嵌合肽及其制备方法 | |
| AU2001271124A1 (en) | Peptides for the preparation of vaccines against bordetella pertussis and bordetella parapertussis | |
| JPS63503197A (ja) | マラリアに対する保護免疫を与えるポリペプチド類 |